Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vortioxetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 20/20 | 0.97 |
| ▸ | HTR3A known ✓ | P46098 | 20/20 | 0.97 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.97 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.97 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.97 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.97 |
| ▸ | HRH2 | P25021 | 2/20 | 0.97 |
| ▸ | HTR1B | P28222 | 2/20 | 0.97 |
| ▸ | HTR2A | P28223 | 2/20 | 0.97 |
| ▸ | HTR2C | P28335 | 2/20 | 0.97 |
| ▸ | HTR7 | P34969 | 2/20 | 0.97 |
| ▸ | HRH1 | P35367 | 2/20 | 0.97 |
| ▸ | HTR5A | P47898 | 2/20 | 0.97 |
| ▸ | HTR6 | P50406 | 2/20 | 0.97 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.97 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vortioxetine SCHEMBL29393393 | 1.00 | HTR1A (0.97) | HTR1AHTR3ACYP1A2CYP3A4CYP2D6 | |
| Vortioxetine SCHEMBL19717678 | 1.00 | HTR1A (0.97) | HTR1AHTR3ACYP1A2CYP3A4CYP2D6 | |
| Vortioxetine SCHEMBL28043138 | 0.99 | HTR1A (0.95) | HTR1AHTR3ACYP1A2CYP3A4CYP2D6 | |
| Vortioxetine SCHEMBL30153367 | 0.99 | HTR1A (0.95) | HTR1AHTR3ACYP1A2CYP3A4CYP2D6 | |
| Vortioxetine SCHEMBL29734869 | 0.99 | HTR1A (0.95) | HTR1AHTR3ACYP1A2CYP3A4CYP2D6 | |
| Vortioxetine SCHEMBL15623040 | 0.99 | HTR1A (1.00) | HTR1AHTR3ACYP1A2CYP3A4CYP2D6 | |
| Vortioxetine SCHEMBL29469584 | 0.99 | HTR1A (1.00) | HTR1AHTR3ACYP1A2CYP3A4CYP2D6 | |
| Vortioxetine SCHEMBL236115 | 0.99 | HTR1A (1.00) | HTR1AHTR3ACYP1A2CYP3A4CYP2D6 | |
| Vortioxetine SCHEMBL966801 | 0.97 | HTR1A (1.00) | HTR1AHTR3ACYP1A2CYP3A4CYP2D6 | |
| Vortioxetine SCHEMBL18687167 | 0.97 | HTR1A (0.97) | HTR1AHTR3ACYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 531 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4566590-A1 | TASTE-MASKING MICROSPHERE, PREPARATION PROCESS THEREFOR, AND USE THEREOF | Harbin Kanon Pharmaceutical Co., Ltd (CN) | 2025-06-11 | — | — | EP | claimed |
| CN-119285512-A | Vortioxetine hydrobromide preparation method of statin intermediate | 上海艾维瑞生物医药科技有限公司 | 2025-01-10 | — | — | CN | claimed |
| CN-115212190-B | Taste-masking vortioxetine oral instant membrane and preparation method thereof | 长沙晶易医药科技股份有限公司 | 2024-08-30 | — | — | CN | claimed |
| CN-117503707-B | Taste-masking microsphere and preparation process and application thereof | 哈尔滨市康隆药业有限责任公司 | 2024-08-23 | — | — | CN | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| US-20240183845-A1 | BILE ACID METABOLITES FOR DIAGNOSING AND TREATING DEPRESSIVE DISORDERS | KADDURAH DAOUK RIMA F (US) | 2024-06-06 | — | — | US | claimed |
| CN-114796222-B | Coated granules, solid dispersions and formulations containing vortioxetine hydrobromide for taste masking in the oral cavity | 普济生物科技（台州）有限公司 | 2024-03-29 | — | — | CN | claimed |
| CN-220588971-U | Rectification system for vortioxetine hydrobromide medicine | 寿光富康制药有限公司 | 2024-03-15 | — | — | CN | claimed |
| WO-2024027794-A1 | TASTE-MASKING MICROSPHERE, PREPARATION PROCESS THEREFOR, AND USE THEREOF | 哈尔滨市康隆药业有限责任公司 | 2024-02-08 | — | — | WO | claimed |
| CN-117503707-A | Taste-masking microsphere and preparation process and application thereof | 哈尔滨市康隆药业有限责任公司 | 2024-02-06 | — | — | CN | claimed |
| EP-2398785-B1 | PURIFICATION OF 1-[2-(2,4-DIMETHYLPHENYLSULFANYL)PHENYL]-PIPERAZINE | LUNDBECK & CO AS H (DK) | 2013-11-27 | — | — | EP | claimed |
| EP-2470166-B1 | NEW COMPOSITIONS OF 1-[2-(2,4-DIMETHYL-PHENYLSULFANYL)-PHENYL]PIPERAZINE | LUNDBECK & CO AS H (DK) | 2013-08-14 | — | — | EP | claimed |
| EP-2439201-B1 | COMPOUNDS WITH COMBINED SERT, 5-HT3 AND 5-HT1A ACTIVITY | LUNDBECK & CO AS H (DK) | 2013-08-07 | — | — | EP | claimed |
| EP-2044043-B1 | 1- Ý[- (2, 4-DIMETHYLPHENYLSULFANYL) -PHENYL]PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT | LUNDBECK & CO AS H (DK) | 2012-01-11 | — | — | EP | claimed |
| US-20120004409-A1 | Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine | H. LUNDBECK A/S (DK) | 2012-01-05 | — | — | US | claimed |
| EP-2398785-A1 | PURIFICATION OF 1-Ý2-(2,4-DIMETHYLPHENYLSULFANYL)PHENYL¨PIPERAZINE | H. Lundbeck A/S (DK) | 2011-12-28 | — | — | EP | claimed |
| US-20100297240-A1 | 1- [2- (2,4-DIMETHYLPHENYLSULFANYL)-PHENYL] PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT | H. LUNDBECK A/S (DK) | 2010-11-25 | — | — | US | claimed |
| WO-2010094285-A1 | PURIFICATION OF 1-[2-(2,4-DIMETHYLPHENYLSULFANYL)PHENYL]PIPERAZINE | H. LUNDBECK A/S (DK) | 2010-08-26 | — | — | WO | claimed |
| EP-2044043-A1 | 1- Ý[- (2, 4-DIMETHYLPHENYLSULFANYL) -PHENYL]PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT | H.Lundbeck A/S (DK) | 2009-04-08 | — | — | EP | claimed |
| WO-2007144005-A1 | 1- [2- (2, 4-DIMETHYLPHENYLSULFANYL) -PHENYL] PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT | H. LUNDBECK A/S (DK) | 2007-12-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100297240-A1 | 1- [2- (2,4-DIMETHYLPHENYLSULFANYL)-PHENYL] PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT | HTR3A, HTR2C, HTR5A | HTR1A 5/4885HTR3A 1/4885SLC6A4 20/4885 |
| US-20120004409-A1 | Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine | NPEPPS, PLP2, DHPS | HTR1A 162/4885HTR3A 476/4885SLC6A4 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.